GlassScriptPhysician profile
Doreena Tran
NPI 1487147286
$10,016.69
in general payments reported to CMS, 2019-2025
30 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,495 · 2022: $2,733 · 2023: $3,191 · 2024: $2,065 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,734 · Education: $55.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,734.31 |
| Education | $55.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,966.00 | 2021-2025 | |
| Amgen INC. | $1,186.31 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,013.55 | 2021-2024 | |
| Janssen Biotech, INC. | $909.50 | 2021-2024 | Tremfya, Simponi, Stelara |
| Astrazeneca Pharmaceuticals LP | $507.53 | 2021-2025 | Saphnelo, Airsupra |
| Glaxosmithkline, LLC. | $421.05 | 2021-2024 | Benlysta |
| Ani Pharmaceuticals, INC. | $350.43 | 2023-2024 | Purified Cortrophin Gel |
| Lilly USA, LLC | $322.21 | 2021-2025 | Taltz, Mounjaro, Zepbound |
| Ucb, INC. | $297.93 | 2021-2024 | Cimzia |
| Pfizer INC. | $260.44 | 2022-2024 | |
| Aurinia Pharma U.S., INC. | $241.60 | 2021-2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.19 | 2023-2025 | Cyltezo, Ofev, Jardiance |
| Horizon Therapeutics Plc | $231.04 | 2022-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $196.70 | 2021-2024 | Orencia |
| Novo Nordisk INC | $180.43 | 2025 | Wegovy, Ozempic |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $142.22 | 2022-2024 | Tymlos |
| Janssen Scientific Affairs, LLC | $139.37 | 2021-2022 | |
| Corcept Therapeutics | $73.80 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $52.99 | 2021 | |
| Astellas Pharma US INC | $43.86 | 2025 | Veozah |
| Tersera Therapeutics LLC | $39.54 | 2023 | Quzyttir |
| Alexion Pharmaceuticals, INC. | $36.72 | 2021-2023 | Ultomiris |
| Organon LLC | $33.01 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $27.81 | 2021 | |
| Fresenius Kabi USA, LLC | $20.59 | 2024 | Idacio |
| Bayer Healthcare Pharmaceuticals INC. | $19.54 | 2025 | |
| Renalytix Ai, INC. | $18.43 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Exact Sciences Corporation | $17.99 | 2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $16.75 | 2023 | Actemra |
| Bioventus LLC | $15.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doreena Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.